IPSC
NASDAQCentury Therapeutics Inc.
Website
News25/Ratings12
News · 26 weeks63-69%
2025-10-262026-04-19
Mix2990d
- Insider16(55%)
- SEC Filings8(28%)
- Other4(14%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form PRE 14A filed by Century Therapeutics Inc.PRE 14A - Century Therapeutics, Inc. (0001850119) (Filer)
- INSIDERSEC Form 4 filed by Murphy Martin Patrick4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSEC Form 3 filed by new insider Murphy Martin Patrick3 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSEC Form 4 filed by Cowan Chad4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- SECCentury Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Century Therapeutics, Inc. (0001850119) (Filer)
- SECSEC Form 424B5 filed by Century Therapeutics Inc.424B5 - Century Therapeutics, Inc. (0001850119) (Filer)
- INSIDERSVP Finance & Operations Carr Douglas sold $17,953 worth of shares (7,043 units at $2.55), decreasing direct ownership by 1% to 507,261 units (SEC Form 4)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDEROfficer Russotti Gregory sold $25,684 worth of shares (10,076 units at $2.55), decreasing direct ownership by 2% to 515,427 units (SEC Form 4)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERPresident and CEO Pfeiffenberger Brent covered exercise/tax liability with 55,397 shares, decreasing direct ownership by 1% to 3,710,958 units (SEC Form 4)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERChief Scientific Officer Cowan Chad covered exercise/tax liability with 1,431 shares, decreasing direct ownership by 0.12% to 1,177,045 units (SEC Form 4)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- SECSEC Form S-8 filed by Century Therapeutics Inc.S-8 - Century Therapeutics, Inc. (0001850119) (Filer)
- SECSEC Form 8-K filed by Century Therapeutics Inc.8-K - Century Therapeutics, Inc. (0001850119) (Filer)
- SECSEC Form 10-K filed by Century Therapeutics Inc.10-K - Century Therapeutics, Inc. (0001850119) (Filer)
- PRCentury Therapeutics Reports Full Year 2025 Financial Results and Business UpdatesCNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial clinical data in 2H 2027CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion™ 5.0, on track to enter the clinic in 2026Strengthened balance sheet and cash runway extended into 1Q 2029 from oversubscribed $135 million private placement in January 2026 PHILADELPHIA, March 12, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoi
- INSIDERSEC Form 4 filed by Century Therapeutics Inc.4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSVP Finance & Operations Carr Douglas sold $626 worth of shares (247 units at $2.54), decreasing direct ownership by 0.05% to 514,304 units (SEC Form 4)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERPresident and CEO Pfeiffenberger Brent covered exercise/tax liability with 463 shares, decreasing direct ownership by 0.01% to 3,766,355 units (SEC Form 4)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- PRCentury Therapeutics to Participate in Upcoming Investor Conferences in MarchPHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced that the company will participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference: Fireside chat at 9:50 a.m. ET on Wednesday, March 4, 2026, in Boston, MA. Leerink Partners Global Healthcare Conference: Fireside chat at 4:20 p.m. ET on Tuesday, March 10, 2026, in Miami, FL. A live webcast of the presentations will be available on the Investors page of Century's
- ANALYSTTD Cowen initiated coverage on Century TherapeuticsTD Cowen initiated coverage of Century Therapeutics with a rating of Buy
- INSIDERPresident and CEO Pfeiffenberger Brent covered exercise/tax liability with 31,172 shares, decreasing direct ownership by 0.82% to 3,766,818 units (SEC Form 4)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- SECSEC Form EFFECT filed by Century Therapeutics Inc.EFFECT - Century Therapeutics, Inc. (0001850119) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Century Therapeutics Inc.SCHEDULE 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
- PRIPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightNew York, USA, Feb. 16, 2026 (GLOBE NEWSWIRE) -- IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and commercial analysis. DelveInsight's 'IPSC-derived NK Cells Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for IPSC-derived NK cells across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitiv
- INSIDERSVP Finance & Operations Carr Douglas sold $589 worth of shares (323 units at $1.82), decreasing direct ownership by 0.06% to 514,551 units (SEC Form 4)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- SECSEC Form S-3 filed by Century Therapeutics Inc.S-3 - Century Therapeutics, Inc. (0001850119) (Filer)